INCB 59872

Drug Profile

INCB 59872

Alternative Names: INCB 059872; INCB59872

Latest Information Update: 21 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Incyte Corporation
  • Class Antianaemics; Antineoplastics
  • Mechanism of Action Lysine specific demethylase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Cancer
  • Phase I Sickle cell anaemia
  • Preclinical Prostate cancer

Most Recent Events

  • 02 May 2018 Incyte Corporation plans a phase I trial for Ewing's-sarcoma in June 2018 , (NCT03514407)
  • 15 Mar 2018 Preclinical trials in Prostate cancer in USA (PO)
  • 03 May 2017 Incyte Corporation plans a phase I trial for Sickle cell anaemia in USA (NCT03132324)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top